155 related articles for article (PubMed ID: 2669998)
21. Extended triple intrathecal chemotherapy trial for prevention of CNS relapse in good-risk and poor-risk patients with B-progenitor acute lymphoblastic leukemia: a Pediatric Oncology Group study.
Pullen J; Boyett J; Shuster J; Crist W; Land V; Frankel L; Iyer R; Backstrom L; van Eys J; Harris M
J Clin Oncol; 1993 May; 11(5):839-49. PubMed ID: 8487048
[TBL] [Abstract][Full Text] [Related]
22. Risk- and response-based classification of childhood B-precursor acute lymphoblastic leukemia: a combined analysis of prognostic markers from the Pediatric Oncology Group (POG) and Children's Cancer Group (CCG).
Schultz KR; Pullen DJ; Sather HN; Shuster JJ; Devidas M; Borowitz MJ; Carroll AJ; Heerema NA; Rubnitz JE; Loh ML; Raetz EA; Winick NJ; Hunger SP; Carroll WL; Gaynon PS; Camitta BM
Blood; 2007 Feb; 109(3):926-35. PubMed ID: 17003380
[TBL] [Abstract][Full Text] [Related]
23. Correlation of karyotype and immunophenotype in childhood acute lymphoblastic leukemia; experience at the National Cancer Institute, Cairo University, Egypt.
Hamouda F; El-Sissy AH; Radwan AK; Hussein H; Gadallah FH; Al-Sharkawy N; Sedhom E; Ebeid E; Salem SI
J Egypt Natl Canc Inst; 2007 Jun; 19(2):87-95. PubMed ID: 19034338
[TBL] [Abstract][Full Text] [Related]
24. Significance of the complete clearance of peripheral blasts after 7 days of prednisolone treatment in children with acute lymphoblastic leukemia: the Tokyo Children's Cancer Study Group Study L99-15.
Manabe A; Ohara A; Hasegawa D; Koh K; Saito T; Kiyokawa N; Kikuchi A; Takahashi H; Ikuta K; Hayashi Y; Hanada R; Tsuchida M;
Haematologica; 2008 Aug; 93(8):1155-60. PubMed ID: 18519521
[TBL] [Abstract][Full Text] [Related]
25. Long-term outcome in children with relapsed ALL by risk-stratified salvage therapy: results of trial acute lymphoblastic leukemia-relapse study of the Berlin-Frankfurt-Münster Group 87.
Einsiedel HG; von Stackelberg A; Hartmann R; Fengler R; Schrappe M; Janka-Schaub G; Mann G; Hählen K; Göbel U; Klingebiel T; Ludwig WD; Henze G
J Clin Oncol; 2005 Nov; 23(31):7942-50. PubMed ID: 16258094
[TBL] [Abstract][Full Text] [Related]
26. Methotrexate polyglutamation may lack prognostic significance in children with B-cell precursor acute lymphoblastic leukemia treated with intensive oral methotrexate.
Mantadakis E; Smith AK; Hynan L; Winick NJ; Kamen BA
J Pediatr Hematol Oncol; 2002 Nov; 24(8):636-42. PubMed ID: 12439035
[TBL] [Abstract][Full Text] [Related]
27. Childhood acute lymphoblastic leukemia immunophenotypes and their prognostic significance: experience of the IGCI-study in 389 children. International Society for Chemo-immunotherapy (IGCI-Vienna) Cooperative Group.
Holowiecki J; Koehler M; Zintl Z; Kardos G; Lutz D; Krzemien S; Rewesz T; Brugiatelli M; Callea V; Kachel L
Leuk Lymphoma; 1992 Jun; 7(3):225-34. PubMed ID: 1477650
[TBL] [Abstract][Full Text] [Related]
28. Intermediate-dose intravenous methotrexate with intravenous mercaptopurine is superior to repetitive low-dose oral methotrexate with intravenous mercaptopurine for children with lower-risk B-lineage acute lymphoblastic leukemia: a Pediatric Oncology Group phase III trial.
Mahoney DH; Shuster J; Nitschke R; Lauer SJ; Winick N; Steuber CP; Camitta B
J Clin Oncol; 1998 Jan; 16(1):246-54. PubMed ID: 9440749
[TBL] [Abstract][Full Text] [Related]
29. Early and delayed consolidation chemotherapy significantly improves the outcome of children with intermediate risk acute lymphoblastic leukemia. Final results of the prospective randomized PETHEMA ALL-89 TRIAL.
Ortega JJ; Ribera JM; Oriol A; Bastida P; González ME; Calvo C; Egurbide I; Hernández Rivas JM; Rivas C; Alcalá A; Besalduch J; Maciá J; Gardella S; Carnero M; Lite JM; Casanova F; Martinez M; Fontanillas M; Feliu E; San Miguel JF;
Haematologica; 2001 Jun; 86(6):586-95. PubMed ID: 11418367
[TBL] [Abstract][Full Text] [Related]
30. Results of therapy for acute lymphoblastic leukemia in black and white children.
Pui CH; Sandlund JT; Pei D; Rivera GK; Howard SC; Ribeiro RC; Rubnitz JE; Razzouk BI; Hudson MM; Cheng C; Raimondi SC; Behm FG; Downing JR; Relling MV; Evans WE
JAMA; 2003 Oct; 290(15):2001-7. PubMed ID: 14559953
[TBL] [Abstract][Full Text] [Related]
31. Early response to induction therapy as a predictor of disease-free survival and late recurrence of childhood acute lymphoblastic leukemia: a report from the Childrens Cancer Study Group.
Miller DR; Coccia PF; Bleyer WA; Lukens JN; Siegel SE; Sather HN; Hammond GD
J Clin Oncol; 1989 Dec; 7(12):1807-15. PubMed ID: 2685179
[TBL] [Abstract][Full Text] [Related]
32. A comparison of early intensive methotrexate/mercaptopurine with early intensive alternating combination chemotherapy for high-risk B-precursor acute lymphoblastic leukemia: a Pediatric Oncology Group phase III randomized trial.
Lauer SJ; Shuster JJ; Mahoney DH; Winick N; Toledano S; Munoz L; Kiefer G; Pullen JD; Steuber CP; Camitta BM
Leukemia; 2001 Jul; 15(7):1038-45. PubMed ID: 11455971
[TBL] [Abstract][Full Text] [Related]
33. High-dose methotrexate improves clinical outcome in children with acute lymphoblastic leukemia: St. Jude Total Therapy Study X.
Abromowitch M; Ochs J; Pui CH; Kalwinsky D; Rivera GK; Fairclough D; Look AT; Hustu HO; Murphy SB; Evans WE
Med Pediatr Oncol; 1988; 16(5):297-303. PubMed ID: 3054451
[TBL] [Abstract][Full Text] [Related]
34. Low relapse rate in children with acute lymphoblastic leukemia after risk-directed therapy.
Tzortzatou-Stathopoulou F; Papadopoulou AL; Moschovi M; Botsonis A; Tsangaris GT
J Pediatr Hematol Oncol; 2001 Dec; 23(9):591-7. PubMed ID: 11902303
[TBL] [Abstract][Full Text] [Related]
35. Expression of identical E2A/PBX1 fusion transcripts occurs in both pre-B and early pre-B immunological subtypes of childhood acute lymphoblastic leukemia.
Izraeli S; Henn T; Strobl H; Ludwig WD; Kovar H; Haas OA; Harbott J; Bartram CR; Gadner H; Lion T
Leukemia; 1993 Dec; 7(12):2054-6. PubMed ID: 8255105
[TBL] [Abstract][Full Text] [Related]
36. High cure rate with a moderately intensive treatment regimen in non-high-risk childhood acute lymphoblastic leukemia. Results of protocol ALL VI from the Dutch Childhood Leukemia Study Group.
Veerman AJ; Hählen K; Kamps WA; Van Leeuwen EF; De Vaan GA; Solbu G; Suciu S; Van Wering ER; Van der Does-Van der Berg A
J Clin Oncol; 1996 Mar; 14(3):911-8. PubMed ID: 8622039
[TBL] [Abstract][Full Text] [Related]
37. Improved outcome in childhood acute lymphoblastic leukaemia with reinforced early treatment and rotational combination chemotherapy.
Rivera GK; Raimondi SC; Hancock ML; Behm FG; Pui CH; Abromowitch M; Mirro J; Ochs JS; Look AT; Williams DL
Lancet; 1991 Jan; 337(8733):61-6. PubMed ID: 1670723
[TBL] [Abstract][Full Text] [Related]
38. Long-term results of the AIEOP-ALL-95 Trial for Childhood Acute Lymphoblastic Leukemia: insight on the prognostic value of DNA index in the framework of Berlin-Frankfurt-Muenster based chemotherapy.
Aricò M; Valsecchi MG; Rizzari C; Barisone E; Biondi A; Casale F; Locatelli F; Lo Nigro L; Luciani M; Messina C; Micalizzi C; Parasole R; Pession A; Santoro N; Testi AM; Silvestri D; Basso G; Masera G; Conter V
J Clin Oncol; 2008 Jan; 26(2):283-9. PubMed ID: 18182669
[TBL] [Abstract][Full Text] [Related]
39. Repetitive low dose oral methotrexate and intravenous mercaptopurine treatment for patients with lower risk B-lineage acute lymphoblastic leukemia. A Pediatric Oncology Group pilot study.
Mahoney DH; Camitta BM; Leventhal BG; Shuster JJ; Civin CJ; Ganick DJ; Lauer SJ; Steuber CP; Kamen BA
Cancer; 1995 May; 75(10):2623-31. PubMed ID: 7736409
[TBL] [Abstract][Full Text] [Related]
40. [Initial response to therapy as an important prognostic factor in acute lymphoblastic leukemia in childhood. COALL study group].
Janka-Schaub GE; Stührk H; Kortüm B; Graubner U; Jürgens H; Spaar HJ; Schöck V; Dohrn B; Bahr R; Winkler K
Klin Padiatr; 1991; 203(4):231-5. PubMed ID: 1942930
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
